Mr. Cline brings extensive commercial expertise to lead the transition of Xenon to a commercial-stage company with the anticipated launch of azetukalner across three potential indicationsVANCOUVER, ...

Baker Brothers’ Q1 2025 portfolio reveals biotech investment trends. See more on their top holdings, stake changes, and ...

Alexion has been working hard to flesh out is pipeline as well, snapping up Achillion Pharma, Syntimmune, Wilson Therapeutics and Portola and forging an alliance with gene-silencing specialist ...

Soliris is still the mainstay of Alexion’s business and accounted for ... Infamous for its litigious behaviour in the pharma industry, Amgen lost the latest round in a legal battle with Sanofi ...

AstraZeneca (AZ) has announced promising results from a late-stage study of its C5 complement inhibitor Ultomiris ...

This milestone follows PharmSight’s recent launch in the U.S. market. With offices in Boston and now Zug, PharmSight is planning expansion into the Middle East and establishing an innovation center ...

22 May 2025 AstraZeneca subsidiary Alexion suffers setback in bid to stop rivals launching biosimilars of blood disorder drug | Ruling concerns an error in original patent application | Decision ...